Vinge has advised Röko AB (publ) (“Röko”) in connection with its listing on Nasdaq Stockholm. The prospectus was published on March 4, 2025 and the first day of trading is March 11, 2025.

The offering price was SEK 2,048 per class B share, corresponding to a total market value for all shares in Röko of approximately SEK 29.95 billion. The total value of the offering amounts to approximately SEK 5,284 million.

Röko is a Sweden-based serial acquirer that has completed 28 platform acquisitions in a variety of industries across Europe. The company's ambition is to be the perpetual owner of small and medium-sized businesses. Historically, Röko has primarily acquired small and medium-sized businesses headquartered in the Nordics and Northern Europe. Röko's organization has more than 100 years of combined experience working with founder- and entrepreneur-led companies in a wide range of industries and the individuals in executive management positions have worked at the company since its first year of operation.

Vinge’s team primarily consisted of Linnéa Sellström, Jesper Schönbeck, Erik Sjöman, Lorin Arabi, Annie Fällström, Michaela Ådén, Karin Karsten, Louise Nässén and Lovisa Jonassen (Capital Markets and Public M&A), Victor EricssonEmelie Svanberg, Erik Kochbati, Marcus Svärd and Ellenor Eckerborn (Corporate Tax), Helena Göransson, Nour Makie and William Carlberg Johansson (Financing), Nicklas Thorgerzon, Martin Boström and Elis Allmark (Commercial agreements, IT and GDPR) Johan Gavelin (Intellectual Property), Gulestan Ali (Regulatory) as well as Louisa Fagarasan (Employment).

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026